Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow RIGL by emailGet an email when RIGL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RIGL, unsubscribe in one click. Privacy
📣 What RIGL Says Is Next
second half of 2026 · “The company expects to select the recommended Phase 2 dose in the second half of 2026 and share preliminary dose expansion data by year end.”
Company press release, Aug 4, 2026 · SEC filing
second half of 2026 · “Rigel continues to advance its Phase 1b clinical study of R289 1 , a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS), with enrollment in the dose expansion phase ongoing and on track to be completed in the second half of 2026.”
Company press release, Aug 4, 2026 · SEC filing
second half of 2026 · ““We are also advancing the development of R289 in our ongoing Phase 1b study in patients with R/R lower-risk MDS, and remain on track to complete enrollment in the dose expansion phase of the study, select a recommended Phase 2 dose in the second half of 2026 and share preliminary data by year end.” Second Quarter 2026 Business Update Corporate”
Company press release, Aug 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full RIGL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RIGL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.